4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis

M.D. Anderson Cancer Center75 enrolled

Overview

This trial studies how well 4 dimensional (D) positron emission tomography/computed tomography (PET/CT) works in diagnosing participants with lung or colorectal cancer that has spread to the liver and lung. Diagnostic procedures, such as PET/CT, may help find and diagnose disease and find out how far the disease has spread. But the motions made by breathing can reduce the image quality of the scan. Adjusting the scanner to 4D may allow for more breathing motion may improve the quality of the PET/CT images.

PRIMARY OBJECTIVES: I. Study the impact of 4D positron emission tomography/computed tomography (PET/CT) imaging on the evaluation and staging of lung and colorectal cancer. OUTLINE: Participants undergo 4D PET/CT scan over up to 12 minutes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Malignant Neoplasm in the Liver Metastatic Malignant Neoplasm in the Lung Stage IV Colorectal Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study. * Patients with suspected lung cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study. Exclusion Criteria: * Patients that cannot tolerate being scanned for an additional 12 minutes with arms above their head will be excluded.

Outcomes

Primary Outcomes

Maximum lesion standardized uptake value (SUVmax) for gated and ungated positron emission tomography/computed tomography (PET/CT) scans

Will be compared using a one-sided paired t-test.

Time frame: Up to 10 years

Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients

two nuclear medicine physicians will assess the impact of the difference in SUVmax on the lesion detectablility and staging of the evaluated patients.